Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

A team led by Paul Hergenrother at the University of Illinois Urbana-Champaign has discovered a new antibiotic that exclusively targets gram-negative bacteria and avoids wiping out the ecosystem of ...

Scientists from Cornell University, University of California, San Francisco (UCSF), and elsewhere have found that a surplus of membrane proteins may help bacteria survive antibiotic exposure. These ...

Vancomycin is a common antibiotic used to treat gram-positive bacterial infections. It targets a key building block of the bacterial cell wall called Lipid II, but it can’t reach this lipid in ...

To date combination therapy for infections by CR GNB is not supported by evidence from a series of adequately sized RCTs. However, pre-clinical data and emerging clinical evidence from observational ...

We often hear about bacteria, but what exactly are they? A bacterium is a living organism that consists of a single cell (unicellular). It has ...